et al. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid ...

▎药明康德内容团队编辑甲状腺未分化癌（ATC），也称“甲状腺间变癌”，是甲状腺癌中少见但恶性程度非常高、预后非常差的病理类型，多数患者发现即为IV期。根据《甲状腺未分化癌诊疗专家共识2023》，甲状腺未分化癌患者中位总生存（OS）期仅5个月，1年OS ...

PTC 的遗传标记是 BRAF 基因中的一个特定突变，即 BRAFV600E 突变。存在这种基因突变的患者通常需要使用威罗菲尼这种针对此类突变的药物。但是大 ...

ChristianaCare基因编辑研究所的研究人员使用CRISPR基因编辑工具禁用了一种侵袭性黑色素瘤的耐药性基因突变，仅在肿瘤细胞中恢复对抗癌药物敏感性。 黑素瘤治疗“向前迈进了一大步” 黑色素瘤仍然是最具挑战性的癌症之一，耐药性突变——主要是激活BRAF突变 ...

The longest OS among the cohorts was 43.2 months in patients with BRAFV600E mutations—the longest OS published to date for systematic therapy in ATC. "Patients with anaplastic thyroid carcinoma ...

We have summarized in this article the current state of combination therapy of approved targeted drugs and irradiation. Since the introduction of the first targeted compounds almost (trastuzumab ...

This trial is looking at improving treatment for bowel cancer. It’s for people who have locally advanced bowel cancer with a gene change called BRAFV600E. Read more about A trial looking at targeted ...

Personalized Medicine. 2013;10(4):405-412. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict ...